NOV 17, 202665 MINS READ
Creatine phosphate (phosphocreatine, PCr) functions as a temporal and spatial energy buffer in tissues with high and fluctuating energy demands, particularly cardiac and skeletal muscle, and the central nervous system 1. The creatine kinase (CK) system catalyzes the reversible transfer of the phosphoryl group from PCr to adenosine diphosphate (ADP), regenerating adenosine triphosphate (ATP) at sites of energy consumption 23. This reaction is thermodynamically favorable under physiological conditions and provides immediate ATP replenishment during periods of increased metabolic demand or impaired oxidative phosphorylation.
The clinical rationale for exogenous creatine phosphate administration stems from three core bioenergetic principles:
However, native creatine phosphate exhibits poor membrane permeability due to its high polarity (multiple negative charges at physiological pH), limiting cellular uptake when administered exogenously 123. Consequently, clinical formulations have historically required intramuscular or intravenous routes, and even then, rapid extracellular metabolism by phosphatases reduces bioavailability 12. This pharmacokinetic challenge has driven development of membrane-permeable prodrugs and analogs, discussed in subsequent sections.
Clinical studies in patients with acute myocardial infarction (AMI) have consistently demonstrated that intravenous creatine phosphate administration (2–8 g/day) reduces infarct size, preserves left ventricular function, and decreases arrhythmic burden 19. A pivotal observation is the reduction in creatine phosphokinase (CPK) release—a biomarker of myocardial necrosis—indicating attenuated cardiomyocyte death 16. In the setting of ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), early administration of PCr within the first 8 hours of symptom onset correlates with improved troponin kinetics and reduced incidence of ventricular arrhythmias 14.
Mechanistically, PCr preserves intracellular ATP levels during the critical ischemic period, preventing the cascade of events leading to irreversible cell injury: ATP depletion, loss of ionic homeostasis (Na⁺/K⁺-ATPase failure), calcium overload, and activation of proteolytic enzymes 113. By maintaining ATP availability, PCr also supports the function of membrane ion pumps and reduces the accumulation of lactate and protons, mitigating acidosis-induced contractile dysfunction 11.
A specialized clinical study evaluated creatine phosphate therapy in patients with ischemic heart disease, angina pectoris, and arterial hypertension exhibiting left ventricular diastolic dysfunction of the "hypertrophic" type 4. Doppler echocardiography was performed before and after PCr treatment, measuring the early diastolic filling velocity (E-wave). The study established that an increase in early diastolic filling velocity by ≥10% post-treatment indicates a positive hemodynamic and antianginal response 4. This finding underscores PCr's role in improving myocardial relaxation, likely through enhanced sarcoplasmic reticulum Ca²⁺-ATPase (SERCA) activity and reduced diastolic stiffness secondary to improved energetics.
During cardiac surgery requiring cardiopulmonary bypass, myocardial protection is achieved through cardioplegic arrest. Addition of creatine phosphate (8–10 g) to cardioplegic solutions has been shown to enhance postoperative recovery of contractile function and reduce the incidence of postoperative arrhythmias 19. The mechanism involves preservation of high-energy phosphate stores during the ischemic arrest period, facilitating rapid resumption of normal excitation-contraction coupling upon reperfusion 9. Clinical protocols incorporating PCr in cardioplegia report shorter intensive care unit stays and reduced need for inotropic support 9.
The therapeutic potential of creatine phosphate is constrained by its inability to cross lipid bilayers and the blood-brain barrier (BBB) due to its zwitterionic, highly hydrophilic structure 123. Oral administration is ineffective because PCr is rapidly dephosphorylated by intestinal and hepatic phosphatases 12. Even intravenous PCr exhibits limited tissue penetration and short plasma half-life 23. To address these limitations, research has focused on:
Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) is efficiently phosphorylated by creatine kinase to yield cyclocreatine phosphate (CCrP), which functions analogously to native PCr in the CK reaction 51013. Preclinical studies in rodent models of heart failure induced by isoproterenol demonstrated that CCrP administration (0.4–1.2 g/kg) dose-dependently reduced myocardial injury markers, preserved left ventricular ejection fraction, and inhibited pathological gene expression networks (e.g., miR-137, miR-106b) associated with cardiac remodeling 13. Notably, CCrP at 0.8 g/kg reduced miR-106b expression by 44% and miR-137 by 33-fold compared to saline controls, indicating potent anti-remodeling effects 13.
In a canine model of acute myocardial infarction (1-hour left anterior descending coronary artery occlusion followed by 2-hour reperfusion), cyclocreatine significantly reduced infarct size, neutrophil infiltration, and plasma levels of the injury biomarker Nourin, while immediately restoring contractile function during reperfusion 14. These findings support the translation of CCrP into clinical trials for acute coronary syndromes and heart failure.
Patent literature describes various prodrug strategies to enhance oral bioavailability and tissue penetration of creatine phosphate 1237. Salicyl alcohol esters of PCr, for example, are designed to be hydrolyzed by intracellular esterases, releasing PCr within target cells 7. Acyloxymethyl and pivaloyloxymethyl esters similarly mask the charged phosphate, enabling passive diffusion across membranes; once inside, cytosolic esterases cleave the promoiety, trapping the polar PCr intracellularly 123. These prodrugs have shown promise in preclinical models of ischemia and neurodegenerative disease, with ongoing formulation optimization to balance lipophilicity (for absorption) and aqueous solubility (for parenteral dosing) 123.
While creatine itself crosses the BBB via the SLC6A8 creatine transporter and can modestly elevate brain creatine levels (~10% increase with oral supplementation), native creatine phosphate does not penetrate the BBB due to its polarity 125. This limitation is critical because acute elevation of brain PCr could provide neuroprotection in stroke, traumatic brain injury, and neurodegenerative diseases characterized by bioenergetic failure 5615.
Cyclocreatine and its phosphorylated analog CCrP offer a solution: cyclocreatine crosses the BBB and is phosphorylated in situ by brain creatine kinase, elevating intracellular CCrP levels 5613. Preclinical studies in models of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) have demonstrated that cyclocreatine supplementation improves mitochondrial function, reduces oxidative stress, and delays disease progression 5615.
The patent literature explicitly identifies cyclocreatine phosphate as a therapeutic candidate for brain ischemia (stroke) and Alzheimer's disease 1314. In stroke, the therapeutic window for intervention is narrow (hours), and strategies that rapidly restore ATP levels could salvage penumbral tissue. CCrP's ability to bypass mitochondrial dysfunction and directly replenish ATP makes it an attractive acute neuroprotectant 1314. In Alzheimer's disease, chronic bioenergetic deficits and mitochondrial dysfunction contribute to synaptic failure and neuronal death; long-term CCrP administration could theoretically slow cognitive decline by sustaining neuronal energy metabolism 1315.
Individuals with loss-of-function mutations in the SLC6A8 creatine transporter gene exhibit severe intellectual disability, developmental delay, and muscle hypotonia due to inability to accumulate creatine and creatine phosphate in brain and muscle 56. Standard creatine supplementation is ineffective in these patients because the transporter is non-functional. Membrane-permeable creatine phosphate prodrugs and analogs, which enter cells independently of SLC6A8, represent a potential therapeutic breakthrough for this orphan indication 56. Preclinical proof-of-concept studies are ongoing, with the goal of initiating clinical trials in pediatric creatine transporter deficiency 56.
Early clinical formulations of creatine phosphate for injection contained large amounts of glycine (e.g., 250 mg glycine per 200 mg PCr) as a lyoprotectant and bulking agent 9. However, scaling to higher doses (0.5–1 g PCr per vial) proportionally increased glycine content, resulting in solutions with unacceptably high osmolality and volume, causing local irritation and limiting intramuscular use 9. Furthermore, high-dose intravenous glycine may cause pharmacological interference (glycine is an inhibitory neurotransmitter) 9.
A novel crystalline form of creatine phosphate containing ~30% crystallization water (~6 H₂O molecules per PCr molecule) was developed, exhibiting low hygroscopicity, improved stability, and eliminating the need for glycine 9. This formulation enables preparation of concentrated, isotonic solutions suitable for both intramuscular and intravenous administration at doses up to 1 g or more per injection, meeting the clinical demand for high-dose cardioprotective therapy 9.
Creatine phosphate disodium salt, the conventional clinical form, poses risks of hypernatremia and vascular irritation, particularly in patients with heart failure or renal impairment who require sodium restriction 12. Substitution of sodium with arginine to form creatine phosphate diarginine salt addresses these concerns 12. Arginine, a semi-essential amino acid and nitric oxide precursor, may confer additional cardiovascular benefits (vasodilation, improved endothelial function) and exhibits synergistic cardioprotection with PCr in preclinical models 12. The diarginine salt formulation is being developed as a safer alternative to the disodium salt for chronic and high-dose use 12.
Creatine phosphate and its analogs, particularly cyclocreatine phosphate, have demonstrated antitumor activity in preclinical models 810. The proposed mechanisms include:
A patent describes the use of creatine phosphate or phosphoenolpyruvic acid for treating human tumors, particularly those resistant to chemotherapy 8. While preclinical data are promising, clinical trials in oncology have not been widely reported, and this application remains investigational 810. The disodium salt trihydrate of phosphorylcyclocreatine (C₅H₈N₃O₅P·Na₂·3H₂O) has been synthesized with improved aqueous solubility for potential intravenous administration in cancer patients 10.
Creatine phosphate sodium has been investigated for treatment of shock states induced by trauma, hemorrhage, electrocution, drowning, and mining accidents 11. In experimental hemorrhagic shock models, PCr administration improved survival time, attenuated lactic acidosis (by reducing anaerobic glycolysis), and provided hepatorenal protection 11. The mechanism involves:
Clinical protocols for shock management incorporating PCr are under evaluation, with potential utility in emergency and intensive care settings 11.
Oral creatine supplementation (typically 3–5 g/day creatine monohydrate) is widely used by athletes and has been studied in clinical populations. However, creatine supplementation differs fundamentally from exogenous creatine phosphate therapy:
| Parameter | Oral Creatine Supplementation | Exogenous Creatine Phosphate (IV/IM) |
|---|---|---|
| Time to effect | Weeks (loading phase: 5–7 days at 20 g/day) 12 | Immediate (minutes to hours) 19 |
| Magnitude of PCr increase | Modest (~10% in |
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| XENOPORT INC. | Acute ischemic events (myocardial infarction, stroke), neurodegenerative disorders (Alzheimer's, Parkinson's), and creatine transporter deficiency where rapid intracellular energy replenishment is critical. | Membrane-Permeable Creatine Phosphate Prodrugs | Overcomes poor cellular uptake of native creatine phosphate through esterification strategies (acyloxymethyl, pivaloyloxymethyl esters), enabling oral bioavailability and blood-brain barrier penetration for acute ATP restoration in emergency care situations. |
| Nour Heart Inc. | Acute coronary syndromes (STEMI, NSTEMI), heart failure, cardiac surgery cardioplegia, brain ischemia (stroke), and Alzheimer's disease where bioenergetic failure drives disease progression. | Cyclocreatine Phosphate (CCrP) | Dose-dependent cardioprotection with 44% reduction in miR-106b and 33-fold reduction in miR-137 expression at 0.8 g/kg, significantly reducing infarct size, preserving left ventricular ejection fraction, and immediately restoring contractile function during reperfusion in acute myocardial infarction models. |
| SCHIAPPARELLI FARMACEUTICI S.P.A. | High-dose cardioprotective therapy in acute myocardial infarction (2-8 g/day IV), cardiac surgery cardioplegic solutions (8-10 g), and intensive care settings requiring concentrated isotonic formulations. | Glycine-Free Phosphocreatine Formulation | Crystalline creatine phosphate with ~30% crystallization water (~6 H₂O molecules per PCr), eliminating glycine requirement, enabling high-dose parenteral administration (0.5-1 g per injection) with reduced osmolality and improved stability for intramuscular and intravenous use. |
| GUANGDONG ZONK DRUG R & D LIMITED | Chronic heart failure, renal impairment patients, ischemic heart disease with diastolic dysfunction, and high-dose long-term cardioprotective therapy where sodium load must be minimized. | Creatine Phosphate Diarginine Salt | Substitutes sodium with arginine to eliminate hypernatremia risk and vascular irritation, while providing synergistic cardioprotection through nitric oxide-mediated vasodilation and improved endothelial function in patients requiring sodium restriction. |
| JILIN YINGLIAN BIOPHARMACEUTICAL CO. LTD. | Emergency and critical care management of shock states induced by trauma, hemorrhage, electrocution, drowning, and mining accidents requiring immediate multi-organ bioenergetic support. | Creatine Phosphate Sodium for Shock | Preserves cellular ATP during hemorrhagic and traumatic shock, reduces lactic acidosis by maintaining aerobic metabolism, inhibits ADP-induced platelet aggregation to improve microcirculation, and provides hepatorenal protection with significantly prolonged survival time. |